FDA Grants Breakthrough Designation for Blood Test to Help Diagnose Inaccessible Brain Tumors
LONDON , Jan. 2, 2023. Datar Cancer Genetics Inc announced today that the US Food and Drug Administration (FDA) has granted ' Breakthrough Device Designation ' for its ' TriNetra-Glio ' , a blood test to help in the diagnosis of brain tumors. This is the...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Brain | Brain Cancers | Brain Tumor | Cancer | Cancer & Oncology | Clinical Trials | Food and Drug Administration (FDA) | Genetics | Grants | Neurology | Pharmaceuticals